TG Therapeutics Inc

XNAS:TGTX 4:00:00 PM EDT

31.98

+0.16 (+0.50%)

6:32:10 PM EDT: $31.47 -0.51 (-1.60%)

Market Cap (Intraday)	5.11B
Current PE	11.42
Forward PE	23.17
2yr Forward PE	14.09

See more stats

Estimates Current Quarter

Revenue	$198.16 Million
Adjusted EPS	$0.28

See more estimates

10-Day MA	$30.52
50-Day MA	$29.76
200-Day MA	$32.22

See more pivots

TG Therapeutics Inc Stock, XNAS:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560

United States of America

Phone: +1.212.554.4484

Number of Employees: 338

http://www.tgtherapeutics.com

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.